Literature DB >> 15124242

Functional status and radiographic joint damage are associated with health economic outcomes in patients with rheumatoid arthritis.

Arthur Kavanaugh1, Chenglong Han, Mohan Bala.   

Abstract

OBJECTIVE: This analysis examines the relationship between the functional and radiographic measures of disease activity and the employment status in patients with rheumatoid arthritis (RA). We also assessed the influence of improvement in physical function on employability, healthcare costs, and quality of life, utilizing data collected in the ATTRACT trial.
METHODS: During the ATTRACT trial, the Health Assessment Questionnaire (HAQ) disability index, radiographic damage measured by the van der Heijde modified Sharp (vdH-Sharp) score, employment status, healthcare resource utilization, and quality of life measured by Medical Outcomes Survey Short Form-36 were assessed at baseline and again periodically through Week 54. Clinically important improvement was defined as an improvement in the HAQ of > or = 0.25 from baseline to Week 54.
RESULTS: There was a significant association at baseline between functional status and the percentages of patients employed. Increased radiographic joint damage was associated with lower full-time employment rate, with patients in the 2 highest quartiles (vdH-Sharp score > 51.5) of radiographic damage having lower rates of full-time employment than those with less damage. During the ATTRACT trial, patients who achieved a clinically important improvement in HAQ scores had a significant improvement in their employability (21% vs 3%; p < 0.001), in their time lost from work (7 vs 30 days; p = 0.012), in their total/direct medical costs (7093/6791 US dollars vs 11,712/10,039 US dollars; p < 0.001), and in their quality of life (p < 0.001) compared with those who did not demonstrate this improvement.
CONCLUSION: Functional disability and radiographic joint damage are correlated with employment in patients with RA. Clinically important improvement in HAQ scores is associated with substantial health economic and quality of life benefits for patients with RA.

Entities:  

Mesh:

Year:  2004        PMID: 15124242

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  19 in total

1.  Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.

Authors:  K Puolakka; H Kautiainen; M Pekurinen; T Möttönen; P Hannonen; M Korpela; M Hakala; M Arkela-Kautiainen; R Luukkainen; M Leirisalo-Repo
Journal:  Ann Rheum Dis       Date:  2005-11-16       Impact factor: 19.103

2.  The impact of rheumatoid arthritis and biologics on employers and payers.

Authors:  Paresh Chaudhari
Journal:  Biotechnol Healthc       Date:  2008-07

3.  Evaluation of work disability in Japanese patients with rheumatoid arthritis: from the TOMORROW study.

Authors:  Shohei Anno; Yuko Sugioka; Kentaro Inui; Masahiro Tada; Tadashi Okano; Kenji Mamoto; Tatsuya Koike
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

4.  Digital tomosynthesis as a new diagnostic tool for assessing of chronic gout arthritic feet and ankles: comparison of plain radiography and computed tomography.

Authors:  Chang-Nam Son; Yoonah Song; Sang-Hyon Kim; Seunghun Lee; Jae-Bum Jun
Journal:  Clin Rheumatol       Date:  2017-06-08       Impact factor: 2.980

Review 5.  Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis.

Authors:  Katherine A Lyseng-Williamson; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

6.  Cigarette smoking and radiographic progression in rheumatoid arthritis.

Authors:  A Finckh; S Dehler; K H Costenbader; C Gabay
Journal:  Ann Rheum Dis       Date:  2007-01-19       Impact factor: 19.103

Review 7.  Health economics: implications for novel antirheumatic therapies.

Authors:  A Kavanaugh
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 8.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

9.  Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register.

Authors:  Suzanne M M Verstappen; Kath D Watson; Mark Lunt; Katie McGrother; Deborah P M Symmons; Kimme L Hyrich
Journal:  Rheumatology (Oxford)       Date:  2010-05-05       Impact factor: 7.580

Review 10.  Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.